-
FDA Clears Artificial Pancreas System for Type 1 Diabetes
The Food and Drug Administration cleared for sale a system that automatically monitors blood glucose and maintains basic insulin levels in people with type 1 diabetes.
-
Harvard Spin-Off to Sequence, Visualize RNA in Tissue
A new spin-off enterprise from Harvard University is commercializing technology that enables sequencing and imaging of genetic transcriptions of cells in their original tissue.
-
Spinal Cord Injury Rehab Device in Development
A robotic device to improve the balance of people going through rehabilitation after spinal cord injury is being developed by an engineering-medical team from Columbia University and University of Louisville.
-
Trial Shows Engineered T-Cells Can Stop Lymphoma
Early results of a clinical trial show an individual’s own immune system cells altered to attack non-Hodgkin lymphoma can cause a partial or complete response in a large percentage of patients.
-
DoD Grant Funds Exosome Manufacturing Process
A biotechnology company is receiving a Department of Defense grant to develop a commercial-scale manufacturing process for exosomes, tiny bubbles that deliver drugs to cells in the body.
-
Spin-Off Companies to Develop Chronic Disease Therapies
Two new spin-off enterprises are being created to develop gut-based treatments for chronic diseases using technologies from synthetic biology company Intrexon Corporation.
-
Monsanto Licensing MIT/Harvard Genome Editing
Monsanto Company is licensing genomic editing technology for agricultural applications from a joint research center at Harvard University and MIT.
-
Malnutrition Shown Adding Billions to U.S. Health Costs
An analysis of data from health surveys shows malnutrition associated with 8 common chronic diseases adds $15.5 billion directly to U.S. health care costs.
-
Antibiotic Shown to Control Drug-Resistant Gonorrhea
Findings from a clinical trial show a candidate drug kills bacteria causing a type of gonorrhea becoming resistant to current antibiotics.
-
Genentech, BioNTech Partner on Personal Cancer Therapies
Biotechnology company BioNTech AG is licensing its messenger RNA technology and collaborating with biopharmaceutical company Genentech to develop personalized cancer immunotherapies.